Evidence map›Paper›PMID 37438960›Full record

Trial reportHuman vaccines & immunotherapeutics2023

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez and 6 more

Open access · goldAbstract readRandomized Controlled TrialClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Sue Ann Costa ClemensOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Natalie MarchevskyOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Sarah KellyOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Sally FelleOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Ahmed EldawiOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Rupetha RajasingamOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Rawan MahmudOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Teresa LambeOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Merryn VoyseyOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Isabela GonzalezInstitute for Global Health, University of Siena, Siena, Italy.
Eveline Pipolo MilanCentro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil.
Maria Cleonice JustinoInstituto Evandro Chagas, Health Surveillance Secretariat, Brazilian Ministry of Health, Ananindeua, Pará, Brazil.
Sagida BibiOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Parvinder AleyOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
Ralf ClemensGRID RIO, Rio de Janeiro, Brazil.
Andrew J PollardOxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK.
University of Oxford · GBOxford BioMedica (United Kingdom) · GBInstituto Evandro Chagas · BRNational Grid (United States) · USOxford Biomedical Research · USUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously. Participants received either full-dose of ChAdOx1-S (Group 1,

Indexed as

COVID-19COVID-19 VaccinesAdultBNT162 VaccineBrazilChAdOx1 nCoV-19HumansImmunoglobulin GSARS-CoV-2Single-Blind MethodVaccinationVaccines, InactivatedBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesImmunoglobulin Gsinovac COVID-19 vaccineVaccines, InactivatedBNT162b2ChAdOx1-SCOVID-19fractional doseheterologous boosterneutralizing antibodiesvaccine

Identifiers

PMID37438960
PMCPMC10348030
OpenAlexW4384120427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.